- cafead Dec 07, 2021 at 11:03: AM
via Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases.
Called Odyssey Therapeutics, the startup is backed by OrbiMed Advisors, SR One Capital Management and half a dozen other venture capital firms that collectively staked Glick and his team with the sizable Series A financing round.
article source
Called Odyssey Therapeutics, the startup is backed by OrbiMed Advisors, SR One Capital Management and half a dozen other venture capital firms that collectively staked Glick and his team with the sizable Series A financing round.
article source